accuRx - COPD Florey Survey
The COVID pandemic has meant that delivery of primary care has had to quickly adapt to meet patient needs, especially for those patients considered vulnerable and at risk, such as those with chronic obstructive pulmonary disease (COPD).
A recent report from the Taskforce for Lung Health 1 showed nearly 35,000 people have missed out on a referral for specialist respiratory care, treatment or diagnosis in England during the first lockdown. The need to reach patients remotely and understand how they are managing their chronic conditions is great.
GSK have co-developed and sponsored the delivery of a COPD survey within accuRx to enable patients to complete questions from the COPD Assessment Test (CAT), mMRC dyspnoea scale, their recent exacerbation history and smoking status remotely and shared directly with you in your GP system (EMIS or SystmOne). GSK will receive practice level data relating to the uptake of this survey.
The COPD Assessment Test (CAT) is a clinically validated questionnaire. GSK were supporters of its development, with a multi-disciplinary group of international experts in COPD.
Demo of COPD Florey Questionnaire
Why should you be using accuRx?
- Identify and Prioritise Patients - Floreys can be used across a wide cohort of patients, such as your COPD register, to identify, quickly and remotely, how that population is currently managing their condition which could allow you to prioritise patients for remote reviews.
- Increased Efficiency of Patient Reviews - The information provided by the completed survey, such as CAT score or recent exacerbation history, can also provide important information to make the most efficient use of time within a remote review. It can provide relevant information ahead of a review, which makes efficient use of time during a review and any appropriate interventions required for that patient.
- High Response Rate (approx. 60% for COPD Florey) – Increased patient accessibility due to the digital nature of Floreys, has resulted in a high response rate particularly with those harder to engage demographics of patients, including patients with COPD.
The survey is available to all practices already with the accuRx platform, which accounts for 95% of practices across England, Wales, Northern Ireland and Jersey.